Tegafur (CAS 17902-23-7) is a potent chemotherapeutic agent that functions as a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), within the body. This conversion is key to its effectiveness in combating cancerous cells. The primary mechanism of action for Tegafur involves its metabolite, 5-FU, acting as an antimetabolite. It critically interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase, which is essential for the production of thymidylate, a vital component of DNA. This disruption ultimately leads to the inhibition of cancer cell proliferation and survival.

The therapeutic applications of Tegafur API are primarily focused on oncology. It is widely used in the treatment of various cancers, most notably gastrointestinal cancers such as advanced gastric cancer and colorectal cancer. Often administered in combination with other chemotherapeutic agents or modulating drugs like gimeracil and oteracil (as in the S-1 formulation), Tegafur enhances treatment efficacy and improves patient outcomes. The combination therapies aim to optimize the therapeutic window, increasing the effectiveness of 5-FU while mitigating potential side effects.

At NINGBO INNO PHARMCHEM CO.,LTD., we understand the complex biochemical pathways and therapeutic needs that Tegafur API addresses. Our commitment as a supplier is to provide API of the highest purity, ensuring that it can be effectively formulated into the precise dosages required for these critical medical applications. Pharmaceutical companies rely on the consistent quality of our Tegafur API to develop reliable and effective treatments for patients battling cancer.

The ongoing research into Tegafur and its role in combination therapies continues to expand our understanding of its therapeutic potential. By ensuring a stable supply of high-quality Tegafur API, NINGBO INNO PHARMCHEM CO.,LTD. supports the pharmaceutical industry's efforts to innovate and provide better solutions for cancer patients worldwide. Our dedication to quality and scientific understanding underpins our contribution to advancing cancer care.